The DOI matches its Crossref record; 475 of the 475 references it cites were found in a registry or an index.
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
Open accessAbstract
Monoclonal antibodies (mAbs) have become one of the most important classes of biopharmaceutical products, and they continue to dominate the universe of biopharmaceutical markets in terms of approval and sales. They are the most profitable single product class, where they represent six of the top ten selling drugs. At the beginning of the 1990s, an in vitro antibody selection technology known as antibody phage display was developed by John McCafferty and Sir. Gregory Winter that enabled the discovery of human antibodies for diverse applications, particularly antibody-based drugs. They created combinatorial antibody libraries on filamentous phage to be utilized for generating antigen specific antibodies in a matter of weeks. Since then, more than 70 phage–derived antibodies entered clinical studies and 14 of them have been approved. These antibodies are indicated for cancer, and non-cancer medical conditions, such as inflammatory, optical, infectious, or immunological diseases. Antibody phage display has proven to be a powerful, versatile platform for antibodies discovery and development. This review will illustrate the utility of phage display as a powerful platform for therapeutic antibodies discovery and describe in detail all the approved mAbs derived from phage display.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–475 of 475
Sikic, B. I., Wakelee, H. A., von Mehren, M., Lewis, N. L., Calvert, H., Plummer, E. R., Fox, N. L., Howard, T., Jones, S. F., & Burris, H. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.14006 · Cited by 49
Atezolizumab for the treatment of non-small cell lung cancer
Santini, F. C., & Rudin, C. M. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1356717 · Cited by 49
Eisenhardt, S. U., Schwarz, M., Schallner, N., Soosairajah, J., Bassler, N., Huang, D., Bode, C., & Peter, K. (2006) · Blood · doi:10.1182/blood-2006-03-007179 · Cited by 48
The challenges and molecular approaches surrounding interleukin-2-based therapeutics in cancer
Tang, A., & Harding, F. (2018) · Cytokine X · doi:10.1016/j.cytox.2018.100001 · Cited by 48
Solubility evaluation of murine hybridoma antibodies
Spencer, S. R., Bethea, D., Raju, T., Giles-Komar, J., & Feng, Y. (2012) · mAbs · doi:10.4161/mabs.19869 · Cited by 47
Holzer, T. R., Fulford, A. D., Nedderman, D. M., Umberger, T. S., Hozak, R. R., Joshi, A., Melemed, S. A., Benjamin, L. E., Plowman, G. D., Schade, A. E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080292 · Cited by 47
Walecki, J. M. (2013) · Polish Journal of Radiology · doi:10.12659/pjr.883763 · Cited by 47
Willuda, J., Lindén, L., Lerchen, H., Kopitz, C., Stelte‐Ludwig, B., Peña, C. E., Lange, C., Golfier, S., Kneip, C., Carrigan, P. E., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0474 · Cited by 45
Amatuximab and novel agents targeting mesothelin for solid tumors
Baldo, P., & Cecco, S. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s145105 · Cited by 45
Necitumumab for the Treatment of Advanced Non-Small-Cell Lung Cancer
Díaz-Serrano, A., Sánchez, A., & Paz-Ares, L. G. (2018) · Future Oncology · doi:10.2217/fon-2018-0594 · Cited by 45
Bedinger, D., Lao, L., Khan, S., Lee, S., Takeuchi, T., & Mirza, A. M. (2016) · mAbs · doi:10.1080/19420862.2015.1115166 · Cited by 42
Hultberg, A., Morello, V., Huyghe, L., Jonge, N. D., Blanchetot, C., Hanssens, V., Boeck, G. D., Silence, K., Festjens, E., Heukers, R., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0356 · Cited by 41
An Entirely Cell-Based System to Generate Single-Chain Antibodies against Cell Surface Receptors
Lipes, B. D., Chen, Y.-H., Ma, H., Staats, H. F., Kenan, D. J., & Gunn, M. D. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.03.072 · Cited by 41
Adsorption-Induced Antigenic Changes and Their Significance in Elisa and Immunological Disorders
Butler, J. E., Navarro, P., & Sun, J. Y. (1997) · Immunological Investigations · doi:10.3109/08820139709048914 · Cited by 41
Thatcher, N., Hirsch, F. R., Szczęsna, A., Ciuleanu, T., Szafrański, W., Dediu, M., Ramlau, R., Galiulin, R., Bálint, B., Losonczy, G., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8008 · Cited by 41
Munshi, N. C., Abonour, R., Beck, J. T., et al. (2012) · Blood · doi:10.1182/blood.v120.21.331.331 · Cited by 41
The use of phage display to generate conformation-sensor recombinant antibodies
Haque, A., & Tonks, N. K. (2012) · Nature Protocols · doi:10.1038/nprot.2012.132 · Cited by 40
Therapeutic Antibodies by Phage Display
Shim, H. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160923113714 · Cited by 39
Silkoff, P. E., Flavin, S. K., Gordon, R. M., Loza, M. J., Sterk, P. J., Lutter, R., Diamant, Z., Turner, R. B., Lipworth, B. J., Proud, D., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.06.027 · Cited by 39
Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer
Khan, U., & Shah, M. A. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1656715 · Cited by 39
Watanabe, H., Nakanishi, T., Umetsu, M., & Kumagai, I. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805547200 · Cited by 38
Raum, T., Gruber, R., Riethmüller, G., & Kufer, P. (2001) · Cancer Immunology Immunotherapy · doi:10.1007/pl00006684 · Cited by 38
Construction of scFv Fragments from Hybridoma or Spleen Cells by PCR Assembly
Burmester, J., & Plückthun, A. (2001) · Springer eBooks · doi:10.1007/978-3-662-04605-0_2 · Cited by 37
Reynolds, K. L., Bedard, P. L., Lee, S., Lin, C., Tabernero, J. M., Alsina, M., Cohen, E. E. W., Baselga, J. M., Blumenschein, G. R., Graham, D. M., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3641-6 · Cited by 37
Nobre, C. F., Newman, M. J., DeLisa, A., & Newman, P. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03875-6 · Cited by 37
Marschner, N. W., Rüttinger, D., Zugmaier, G., Nemere, G., Lehmann, J., Obrist, P., Baeuerle, P. A., Wolf, A., Schmidt, M., Abrahamsson, P., et al. (2010) · Urologia Internationalis · doi:10.1159/000318055 · Cited by 36
Epitope-Specific Mechanisms of IGF1R Inhibition by Ganitumab
Calzone, F. J., Cajulis, E. E., Chung, Y.-A., Tsai, M. M., Mitchell, P., Lu, J., Chen, C., Sun, J., Radinsky, R., Kendall, R. L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055135 · Cited by 35
Cook, A. D., & Hamilton, J. A. (2018) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x17752036 · Cited by 35
Graus, Y., Verschuuren, J. J. G. M., Degenhardt, A., Vriesman, P. J. C. V. B., Baets, M. H. D., Posner, J. B., Burton, D. R., & Dalmau, J. O. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(97)00199-9 · Cited by 34
Codon engineering for improved antibody expression in mammalian cells
Carton, J. M., Sauerwald, T. M., Hawley‐Nelson, P., Morse, B. A., Peffer, N. J., Beck, H., Lu, J., Cotty, A., Amegadzie, B. Y., & Sweet, R. (2007) · Protein Expression and Purification · doi:10.1016/j.pep.2007.05.017 · Cited by 34
Elez, E., Hendlisz, A., Delaunoit, T., Sastre, J., Cervantes, A., Varea, R., Chao, G., Wallin, J., & Tabernero, J. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.480 · Cited by 33
Main, S. H., Handy, R. L. C., Wilton, J., Smith, S., Williams, L., Fou, L. D., Andrews, J. L., Conroy, L. A., May, R. D., Anderson, I., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110734 · Cited by 32
A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF
Krinner, E.-M., Raum, T., Petsch, S., Bruckmaier, S., SCHUSTER, I., Petersen, L., Cierpka, R., ABEBE, D., Mølhøj, M., & WOLF, A. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2006.03.020 · Cited by 31
Lee, S. J., Lee, S. Y., Lee, W. S., Yoo, J. S., Sun, J., Lee, J., Park, S. H., Park, J. O., Ahn, M., Lim, H. Y., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0463-y · Cited by 31
Krinner, E.-M., Hepp, J., Hoffmann, P., Bruckmaier, S., Petersen, L., Petsch, S., Parr, L., Schuster, I., Mangold, S., Lorenczewski, G., et al. (2006) · Protein Engineering Design and Selection · doi:10.1093/protein/gzl031 · Cited by 30
Blocking Agent Optimization for Nonspecific Binding on Phage Based Magnetoelastic Biosensors
Shen, W., Li, S., Park, M., Zhang, Z., Cheng, Z. ‐., Petrenko, V. A., & Chin, B. A. (2012) · Journal of The Electrochemical Society · doi:10.1149/2.057210jes · Cited by 29
Kaleli, N. E., Karadag, M., & Kalyoncu, S. (2019) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25685 · Cited by 29
Curley, M. D., Sabnis, G. J., Wille, L., Adiwijaya, B. S., García, G., Moyo, V. M., Kazi, A. A., Brodie, A., & MacBeath, G. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0169 · Cited by 28
Blažek, D., Celer, V., Navratilova, I. H., & Skládal, P. (2003) · Journal of Virological Methods · doi:10.1016/j.jviromet.2003.09.020 · Cited by 27
Lin, B., Renshaw, M. W., Autote, K., Smith, L. M., Calveley, P., Bowdish, K. S., & Frederickson, S. (2008) · Protein Expression and Purification · doi:10.1016/j.pep.2008.01.002 · Cited by 25
Prassler, J., Steidl, S., & Urlinger, S. (2009) · Immunotherapy · doi:10.2217/imt.09.23 · Cited by 25
Fala, L. (2016) · Europe PMC (PubMed Central) · Cited by 25
Belch, A. R., Sharma, A., Spencer, A. G., Tarantolo, S., Bahlis, N. J., Doval, D., Gallant, G., Kumm, E., Klein, J. L., & Chanan-Khan, A. A. (2010) · Blood · doi:10.1182/blood.v116.21.5031.5031 · Cited by 25
High-throughput retrieval of physical DNA for NGS-identifiable clones in phage display library
Noh, J., Kim, O., Jung, Y., Han, H., Kim, J., Kim, S., Lee, S., Park, J., Jung, R. H., Kim, S. I., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1571878 · Cited by 25
Bauer, J., Mathias, S., Kube, S., Otte, K., Garidel, P., Gamer, M., Blech, M., Fischer, S., & Karow‐Zwick, A. R. (2020) · mAbs · doi:10.1080/19420862.2020.1787121 · Cited by 25
Structural diversity and flexibility of diabodies
Kwon, N., Kim, Y., & Lee, J. (2018) · Methods · doi:10.1016/j.ymeth.2018.09.005 · Cited by 24
A review of avelumab in locally advanced and metastatic bladder cancer
Rao, A., & Patel, M. R. (2019) · Therapeutic Advances in Urology · doi:10.1177/1756287218823485 · Cited by 24
Kreitman, R. J., & Pastan, I. H. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0370 · Cited by 24
Kim, S., Park, I., Park, S. G., Cho, S., Kim, J., Ipper, N. S., Choi, S. S., Lee, E. S., & Hong, H. J. (2017) · Molecules and Cells · doi:10.14348/molcells.2017.0106 · Cited by 24
TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis
Lee, W. S., Pyun, B., Kim, S.-W., Shim, S. R., Nam, J. R., Yoo, J. Y., Jin, Y., Jin, J., Kwon, Y.-G., Yun, C., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1045168 · Cited by 23
Options for Second-Line Treatment in Metastatic Colorectal Cancer.
Lee, J. J., & Sun, W. (2016) · PubMed · Cited by 23
Fala, L. (2015) · PubMed · Cited by 23
Mease, P. J., Jeka, S., Jaller, J. J., Kitumnuaypong, T., Louthrenoo, W., Mann, H. F., Matsievskaia, G., Soriano, E. R., Jia, B., Wang, C., et al. (2017) · The Journal of Rheumatology · doi:10.3899/jrheum.161238 · Cited by 23
Dowlati, A., Vlahovic, G., Natale, R. B., Rasmussen, E., Singh, I., Hwang, Y. C., Rossi, J. M., Bass, M., Friberg, G. R., & Pickett, C. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2145 · Cited by 21
Identification of high affinity HER2 binding antibodies using CHO Fab surface display
Nguyen, A. W., Le, K. C., & Maynard, J. A. (2018) · Protein Engineering Design and Selection · doi:10.1093/protein/gzy004 · Cited by 21
Effect of DNA sequence of Fab fragment on yield characteristics and cell growth of E. coli
Kulmala, A., Huovinen, T., & Lamminmäki, U. (2017) · Scientific Reports · doi:10.1038/s41598-017-03957-6 · Cited by 20
Karapetis, C. S., Clingan, P., Leighl, N. B., Durbin-Johnson, B. P., O'Neill, V. J., & Spigel, D. R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.7535 · Cited by 20
O'Reilly, E. M., Sahai, V., Bendell, J. C., Bullock, A. J., LoConte, N. K., Hatoum, H. A., Ritch, P. S., Hool, H., Leach, J. W., Sanchez, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.279 · Cited by 20
Yoo, D. K., Lee, S. R., Jung, Y., Han, H., Lee, H. K., Han, J., Kim, S., Chae, J., Ryu, T., & Chung, J. (2020) · Biomolecules · doi:10.3390/biom10030421 · Cited by 20
B-cell–targeted therapies in relapsing forms of MS
Dubey, D., Forsthuber, T. G., Flanagan, E. P., Pittock, S. J., & Stüve, O. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000405 · Cited by 19
Efficient Construction and Effective Screening of Synthetic Domain Antibody Libraries
Zadeh, A. S., Grässer, A., Dinter, H., Hermes, M., & Schindowski, K. (2019) · Methods and Protocols · doi:10.3390/mps2010017 · Cited by 19
Selection and characterization of cell binding and internalizing phage antibodies
Zhou, Y., Lequn, Z., & Marks, J. D. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.05.007 · Cited by 18
Carlo‐Stella, C., Guidetti, A., Nicola, M. D., Lavazza, C., Cleris, L., Sia, D., Longoni, P. D., Milanesi, M., Magni, M., Nagy, Z. A., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3744 · Cited by 18
VEGF mRNA and protein concentrations in the developing human eye
Irene, T., McConaghy, S., Namachivayam, K., Halloran, B., Kurundkar, A., MohanKumar, K., Maheshwari, A., & Ohls, R. K. (2015) · Pediatric Research · doi:10.1038/pr.2015.15 · Cited by 15
Tesar, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.8106 · Cited by 15
Systemic Therapy for Merkel Cell Carcinoma: What’s on the Horizon?
Rabinowits, G. (2014) · Cancers · doi:10.3390/cancers6021180 · Cited by 14
Takahashi, S., Kobayashi, T., Tomomatsu, J., Ito, Y., Oda, H., Kajitani, T., Kakizume, T., Tajima, T., Takeuchi, H., Maacke, H., et al. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3214-4 · Cited by 14
Liu, M., Zhang, H., Jimenez, X., Ludwig, D. L., Witte, L., Böhlen, P., Hicklin, D., & Zhu, Z. (2004) · Cancer Research · Cited by 14
Kelly, K. L., Heery, C. R., Patel, M. R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3055 · Cited by 12
Rexer, H., & Doehn, C. (2016) · Der Urologe · doi:10.1007/s00120-016-0188-0 · Cited by 11
Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer
Pegram, M. D., Zong, Y., Yam, C., Goetz, M. P., & Moulder, S. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200715 · Cited by 11
Raab, M. S., Chatterjee, M., Goldschmidt, H., Agis, H., Blau, I. W., Einsele, H., Engelhardt, M. M., Ferstl, B., Gramatzki, M., Röllig, C., et al. (2015) · Blood · doi:10.1182/blood.v126.23.3035.3035 · Cited by 11
Mackey, J., Ramos-Vázquez, M., Липатов, О. Н., McCarthy, N. J., Kraznozhon, D., Семиглазов, В. Ф., Manikhas, A., Gelmon, K. A., Konecny, G. E., Webster, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.sabcs13-s5-04 · Cited by 10
Wittebol, S., Ferrant, A., Wickham, N. W., Fehrenbacher, L., Durbin-Johnson, B., & Bray, G. L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.e18511 · Cited by 8
Alfaleh, M. A., Arora, N., Yeh, M., de Bakker, C. J., Howard, C. B., Macpherson, P., Allavena, R., Chen, X., Harkness, L., Mahler, S. M., et al. (2019) · Antibodies · doi:10.3390/antib8010015 · Cited by 5
Self-citation
Cited by
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J.-Y., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 155
Animal immunization, in vitro display technologies, and machine learning for antibody discovery
Laustsen, A. H., Greiff, V., Karatt-Vellatt, A., Muyldermans, S., & Jenkins, T. P. (2021) · Trends in Biotechnology · doi:10.1016/j.tibtech.2021.03.003 · Cited by 147
Generation of peptides using phage display technology for cancer diagnosis and molecular imaging
Pung, H. S., Tye, G. J., Leow, C. H., Ng, W. K., & Lai, N. S. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08380-x · Cited by 30
Generation and diversification of recombinant monoclonal antibodies
DeLuca, K. F., Mick, J. E., Ide, A. H., Lima, W. C., Sherman, L., Schaller, K. L., Anderson, S. M., Zhao, N., Stasevich, T. J., Varma, D., et al. (2021) · eLife · doi:10.7554/elife.72093 · Cited by 21
Arsiwala, A., Bhatt, R., van Niekerk, L., Quintero-Cadena, P., Ao, X., Rosenbaum, A., Bhatt, A., Smith, A., Yang, Y., Anderson, K., et al. (2025) · mAbs · doi:10.1080/19420862.2025.2593055 · Cited by 16
Metadata
- Authors
- Alfaleh, M. A., Alsaab, H. O., Mahmoud, A. B., Alkayyal, A. A., Jones, M. L., Mahler, S. M., & Hashem, A. M.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-08-28
- Volume
- 11
- Pages
- 1986-1986
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3044690826
- Cited by
- 273
- References
- 475
- FWCI
- 14.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.